WO2004056311A3 - Stimuli-responsive systems for controlled drug delivery - Google Patents

Stimuli-responsive systems for controlled drug delivery Download PDF

Info

Publication number
WO2004056311A3
WO2004056311A3 PCT/US2003/040393 US0340393W WO2004056311A3 WO 2004056311 A3 WO2004056311 A3 WO 2004056311A3 US 0340393 W US0340393 W US 0340393W WO 2004056311 A3 WO2004056311 A3 WO 2004056311A3
Authority
WO
WIPO (PCT)
Prior art keywords
stimuli
drug delivery
controlled drug
responsive systems
cross
Prior art date
Application number
PCT/US2003/040393
Other languages
French (fr)
Other versions
WO2004056311A9 (en
WO2004056311A2 (en
Inventor
Todd C Zion
Andrey Zarur
Jackie Y Ying
Original Assignee
Massachusetts Inst Technology
Todd C Zion
Andrey Zarur
Jackie Y Ying
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Inst Technology, Todd C Zion, Andrey Zarur, Jackie Y Ying filed Critical Massachusetts Inst Technology
Priority to AU2003301064A priority Critical patent/AU2003301064A1/en
Priority to CA002509382A priority patent/CA2509382A1/en
Publication of WO2004056311A2 publication Critical patent/WO2004056311A2/en
Publication of WO2004056311A3 publication Critical patent/WO2004056311A3/en
Publication of WO2004056311A9 publication Critical patent/WO2004056311A9/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

A method of delivering a therapeutic agent by providing a cross-linked polymer encapsulating the therapeutic agent to a site in a patient. The degradation rate of the cross-linked polymer is correlated with a local concentration of an indicator, and the therapeutic agent is released as the cross-linked polymer degrades.
PCT/US2003/040393 2002-12-17 2003-12-17 Stimuli-responsive systems for controlled drug delivery WO2004056311A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2003301064A AU2003301064A1 (en) 2002-12-17 2003-12-17 Stimuli-responsive systems for controlled drug delivery
CA002509382A CA2509382A1 (en) 2002-12-17 2003-12-17 Stimuli-responsive systems for controlled drug delivery

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43407602P 2002-12-17 2002-12-17
US60/434,076 2002-12-17

Publications (3)

Publication Number Publication Date
WO2004056311A2 WO2004056311A2 (en) 2004-07-08
WO2004056311A3 true WO2004056311A3 (en) 2004-08-12
WO2004056311A9 WO2004056311A9 (en) 2006-03-30

Family

ID=32681993

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/040393 WO2004056311A2 (en) 2002-12-17 2003-12-17 Stimuli-responsive systems for controlled drug delivery

Country Status (4)

Country Link
US (3) US7531191B2 (en)
AU (1) AU2003301064A1 (en)
CA (1) CA2509382A1 (en)
WO (1) WO2004056311A2 (en)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7163918B2 (en) * 2000-08-22 2007-01-16 New River Pharmaceuticals Inc. Iodothyronine compositions
US7431710B2 (en) 2002-04-08 2008-10-07 Glaukos Corporation Ocular implants with anchors and methods thereof
US8603514B2 (en) 2002-04-11 2013-12-10 Monosol Rx, Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US8900498B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for manufacturing a resulting multi-layer pharmaceutical film
US20110033542A1 (en) 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
US20070281003A1 (en) 2001-10-12 2007-12-06 Fuisz Richard C Polymer-Based Films and Drug Delivery Systems Made Therefrom
US10285910B2 (en) 2001-10-12 2019-05-14 Aquestive Therapeutics, Inc. Sublingual and buccal film compositions
US8900497B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for making a film having a substantially uniform distribution of components
US7357891B2 (en) 2001-10-12 2008-04-15 Monosol Rx, Llc Process for making an ingestible film
US20190328679A1 (en) 2001-10-12 2019-10-31 Aquestive Therapeutics, Inc. Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US8765167B2 (en) 2001-10-12 2014-07-01 Monosol Rx, Llc Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US11207805B2 (en) 2001-10-12 2021-12-28 Aquestive Therapeutics, Inc. Process for manufacturing a resulting pharmaceutical film
JP5026956B2 (en) * 2004-05-12 2012-09-19 サーモディクス，インコーポレイティド Natural biodegradable polysaccharide coating for medical devices
CA2621597C (en) * 2005-09-21 2014-06-10 Surmodics, Inc. In vivo formed matrices including natural biodegradable polysaccharides and ophthalmic uses thereof
ATE540705T1 (en) * 2005-09-21 2012-01-15 Surmodics Inc COVERS AND ARTICLES WITH NATURAL BIODEGRADABLE POLYSACCHARIDES
WO2007044468A2 (en) * 2005-10-05 2007-04-19 The Cbr Institute For Biomedical Research, Inc. Method to treat flavivirus infection with sirna
US20070099820A1 (en) * 2005-10-19 2007-05-03 Smartcells, Inc. Polymer-drug conjugates
WO2008060359A2 (en) * 2006-09-29 2008-05-22 Surmodics, Inc. Biodegradable ocular implants and methods for treating ocular conditions
CA2723192A1 (en) 2008-05-07 2009-11-12 Surmodics, Inc. Delivery of nucleic acid complexes from particles
EA027757B1 (en) 2009-01-28 2017-08-31 Смартселлз, Инк. Conjugate for controlled insulin delivery
EP2391646B1 (en) * 2009-01-28 2016-08-10 Smartcells, Inc. Crystalline insulin-conjugates
JP2012516340A (en) 2009-01-28 2012-07-19 スマートセルズ・インコーポレイテツド Synthetic conjugates and uses thereof
CA2750223A1 (en) 2009-01-28 2010-08-05 Smartcells, Inc. Exogenously triggered controlled release materials and uses thereof
CA2750245A1 (en) * 2009-01-28 2010-08-05 Smartcells, Inc. Polynucleotide aptamer-based cross-linked materials and uses thereof
US9095623B2 (en) 2009-03-20 2015-08-04 Smartcells, Inc. Terminally-functionalized conjugates and uses thereof
US8569231B2 (en) 2009-03-20 2013-10-29 Smartcells, Inc. Soluble non-depot insulin conjugates and uses thereof
WO2010107519A1 (en) 2009-03-20 2010-09-23 Smartcells, Inc. Terminally-functionalized conjugates and uses thereof
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
CN102639009B (en) 2009-07-10 2016-01-20 林齐·O·斯科特三世 For to reduce the medical conditions associated method and composition of Treatment with Folic Acid thyroid gland
US8741591B2 (en) 2009-10-09 2014-06-03 The Research Foundation For The State University Of New York pH-insensitive glucose indicator protein
IL223022A0 (en) 2010-05-14 2013-02-03 Texas A & M Univ Sys Functional, cross-linked nanostructures for tandem optical imaging and therapy
US8790704B2 (en) 2010-06-10 2014-07-29 Monosol Rx, Llc Combination peptide-nanoparticles and delivery systems incorporating same
JP2013541500A (en) 2010-07-28 2013-11-14 スマートセルズ・インコーポレイテツド Recombinant lectins, binding site modified lectins and their uses
CA2805739A1 (en) 2010-07-28 2012-02-02 Smartcells, Inc. Drug-ligand conjugates, synthesis thereof, and intermediates thereto
JP2013535467A (en) 2010-07-28 2013-09-12 スマートセルズ・インコーポレイテツド Recombinantly expressed insulin polypeptide and uses thereof
US9149959B2 (en) 2010-10-22 2015-10-06 Monosol Rx, Llc Manufacturing of small film strips
US8901092B2 (en) 2010-12-29 2014-12-02 Surmodics, Inc. Functionalized polysaccharides for active agent delivery
US20130323293A1 (en) * 2011-02-24 2013-12-05 Takuya Umemoto Glp-1 analogue composition for microneedle devices
US10245178B1 (en) 2011-06-07 2019-04-02 Glaukos Corporation Anterior chamber drug-eluting ocular implant
CN103732215B (en) * 2011-06-10 2017-07-11 莫诺索Rx有限责任公司 Combine peptide nanoparticles and mix its delivery system
JP6735561B2 (en) 2012-12-03 2020-08-05 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． O-glycosylated carboxy-terminal portion (CTP) peptide-based insulin and insulin analogs
CN104109207B (en) 2013-04-17 2017-12-12 上海市肺科医院 Nano antibody of the anti-Surfactant protein A of lung targeted characteristic and preparation method thereof
CN105813652A (en) * 2013-04-30 2016-07-27 麻省理工学院 Injectable nano-network gels for diabetes treatment
BR112016007176A2 (en) 2013-10-04 2018-01-23 Merck Sharp & Dohme conjugate, composition, uses of a conjugate and composition, and method for treating an individual having diabetes
EP3148491B1 (en) 2014-05-29 2020-07-01 Glaukos Corporation Implants with controlled drug delivery features and manufacturing method for said implants
EP3242687B1 (en) * 2015-01-05 2020-12-30 B.G. Negev Technologies and Applications Ltd., at Ben-Gurion University Nanoparticles and methods for preparation thereof
WO2016134002A1 (en) * 2015-02-18 2016-08-25 Memorial Sloan Kettering Cancer Center Compositions and methods for nanoparticle-based drug delivery and imaging
WO2017040853A1 (en) 2015-09-02 2017-03-09 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
US11564833B2 (en) 2015-09-25 2023-01-31 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
CA3022830A1 (en) 2016-04-20 2017-10-26 Harold Alexander Heitzmann Bioresorbable ocular drug delivery device
BR112018072539A2 (en) 2016-05-05 2019-03-26 Aquestive Therapeutics, Inc. increased administration epinephrine compositions
US11273131B2 (en) 2016-05-05 2022-03-15 Aquestive Therapeutics, Inc. Pharmaceutical compositions with enhanced permeation
AU2017300392B2 (en) * 2016-07-18 2022-06-16 Tissuegen, Inc. Methods and compositions for maintaining the conformation and structural integrity of biomolecules
EP3554548A4 (en) 2016-12-19 2020-08-19 The Regents of The University of California Noncrushable pill formulatiions
US11457870B2 (en) * 2017-01-18 2022-10-04 Dexcom, Inc. Sensors for continuous analyte monitoring
NO343313B1 (en) * 2017-03-15 2019-01-28 Lifecare As Fluid composition, method for preparing the composition and use
AR111190A1 (en) 2017-03-22 2019-06-12 Genentech Inc HYDROGEL COMPOSITIONS OF INTERRUPTED DRUGS OF Hyaluronic Acid AND RELATED METHODS
WO2018175272A1 (en) 2017-03-23 2018-09-27 Merck Sharp & Dohme Corp. Glucose responsive insulin comprising a tri-valent sugar cluster for treatment of diabetes
US11045552B2 (en) 2017-04-04 2021-06-29 International Business Machines Corporation Stimulus-responsive micellar carrier
NO20170927A1 (en) * 2017-06-07 2018-12-10 Lifecare As Interstitial fluid osmotic pressure measuring device system and method
US11173212B2 (en) 2017-09-28 2021-11-16 Indian Institute Of Science Education And Research Supramolecular protein assemblies with advanced functions and synthesis thereof
US11820805B2 (en) 2017-12-18 2023-11-21 Merck Sharp & Dohme Llc Conjugate based systems for controlled insulin delivery
US11413352B2 (en) 2017-12-18 2022-08-16 Merck, Sharp & Dohme LLC Conjugate based systems for controlled insulin delivery
US11407791B2 (en) 2018-03-26 2022-08-09 Auctus Biologics, Inc. Compositions, methods, and systems for orally administrable affinity-based protein
EP3893849A4 (en) * 2018-12-14 2022-09-07 Novozymes A/S Nanoparticles based method for screening enzyme or microorganism
HUP1900197A2 (en) * 2019-06-04 2020-12-28 Moow Farm Kft Novel polymer baded substrate indicator combination

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6063116A (en) * 1994-10-26 2000-05-16 Medarex, Inc. Modulation of cell proliferation and wound healing

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4348387A (en) * 1979-07-31 1982-09-07 The Rockefeller University Method and system for the controlled release of biologically active substances to a body fluid
US5707644A (en) * 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
GB9200638D0 (en) * 1992-01-10 1992-03-11 Leicester Polytechnic Drug system
GB9313484D0 (en) 1993-06-30 1993-08-11 Univ Montfort Drug system ii
IE80468B1 (en) * 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
US5814449A (en) * 1996-05-28 1998-09-29 University Of Pittsburgh Homogenous affinity assay for quantitative drug and metabolite determination
AUPO888097A0 (en) * 1997-08-29 1997-09-25 Biotech Australia Pty Limited Cross-linked particles
US5803506A (en) * 1997-09-10 1998-09-08 Flex-Hose Company, Inc. Flexible pipe loop
US6221297B1 (en) * 1999-09-27 2001-04-24 Abb Power T&D Company Inc. Method of manufacturing a transformer coil with a disposable wrap and band mold and integrated winding mandrel
GB0025147D0 (en) * 2000-10-13 2000-11-29 Torsana Diabetes Diagnostics A Optical sensor for in situ measurement of analytes
US6454710B1 (en) * 2001-04-11 2002-09-24 Motorola, Inc. Devices and methods for monitoring an analyte

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6063116A (en) * 1994-10-26 2000-05-16 Medarex, Inc. Modulation of cell proliferation and wound healing

Also Published As

Publication number Publication date
US8357400B2 (en) 2013-01-22
US20090246167A1 (en) 2009-10-01
CA2509382A1 (en) 2004-07-08
AU2003301064A1 (en) 2004-07-14
US20120107371A1 (en) 2012-05-03
US8062668B2 (en) 2011-11-22
US20040202719A1 (en) 2004-10-14
US7531191B2 (en) 2009-05-12
WO2004056311A2 (en) 2004-07-08

Similar Documents

Publication Publication Date Title
WO2004056311A3 (en) Stimuli-responsive systems for controlled drug delivery
WO2004091444A3 (en) Implantable medical device comprising therapeutic agents with different diffusion rates
WO2005009408A3 (en) Sustained release dosage forms of anesthetics for pain management
HRP20050077B1 (en) Methods and dosage forms for controlled delivery of paliperidone
WO2009105432A3 (en) Devices and methods for delivery of a therapeutic agent through a pneumostoma
WO2004087011A3 (en) Therapeutic agent delivery device with controlled therapeutic agent release rates
EP2407203A3 (en) Solid therapeutic agent for use in an implantable drug delivery device
CA2506997A1 (en) Controlled drug delivery using polymer macromolecules to retard drug elution
MXPA02007762A (en) Timed pulsatile drug delivery systems.
WO2005011769A3 (en) Implantable or insertable medical devices containing acrylic copolymer for controlled delivery of therapeutic agent
WO2005074547A3 (en) Inflatable porous implants and methods for drug delivery
WO2005034859A3 (en) Extended release formulations of opioids and method of use thereof
WO2006036970A3 (en) Method of thickening a coating using a drug
WO2009086112A3 (en) Apparatus and methods for delivering therapeutic agents
WO2004011055A3 (en) Implantable or insertable medical devices for controlled drug delivery
WO2002049501A3 (en) Local regional chemotherapy and radiotherapy using in situ hydrogel
WO2001043749A3 (en) Pharmaceutical implant containing immediate-release and sustained-release components and method of administration
WO2004105782A3 (en) Drug delivery systems for tumor targeting ngr-molecules and uses thereof
NO20051964D0 (en) Therapeutic preparations for drug delivery to and through the epithelium
WO2007095600A3 (en) Disintegrable oral films
MXPA04006731A (en) Drug delivery systems for the prevention and treatment of vascular diseases comprising rapamycin and derivatives thereof.
MXPA03010991A (en) Skin-permeable composition comprising a selective cyclooxygenase-2 inhibitor a monohydric alcohol.
AU2003258209A1 (en) Active agent delivery systems, medical devices, and methods
WO2004056305A3 (en) Administration of capsaicinoids
WO2003080022A3 (en) Analgesics for nasal administration

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003301064

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2509382

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004562257

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003813743

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2003813743

Country of ref document: EP

COP Corrected version of pamphlet

Free format text: PAGES 30/33-32/33, DRAWINGS, ADDED

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP